BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Plandai Biotechnology, Inc. (PLPL.OB) Files Revolutionary Patent for Increasing Absorption of Antioxidant Protection


3/9/2012 9:18:48 AM

SEATTLE, WA--(Marketwire - March 09, 2012) - Plandaí Biotechnology, Inc. (OTCBB: PLPL) Chief Executive Officer Roger Duffield, today announced that a patent application has been filed on the company's proprietary process for increasing the absorption of plant phytonutrients, especially antioxidants. The document, which was filed with the U.S. Patent Office on February 14, 2012, covers the process of treating live plant material in a CRS Hydrodynamic Process in order to increase absorption by the body and to efficiently transport and release the phytonutrients into cells. The inventors are Dr. Tom Matula and Mr. Roger Duffield.

According to the literature, live plant materials subjected to the CRS hydrodynamic process releases the phytonutrients and, through the process, alters the stereochemical structure by changing trans-isomers into the cis form, and/or by changing cis-isomers into the trans form. Phytonutrients, such as carotenoids (found in tomatoes) usually have a 95% trans-structure, whereas flavonoids (such as those found in green tea) usually have a 95% cis-structure. The CRS hydrodynamic process alters the isomeric properties of released phytonutrients and rearranges them to a ratio more readily absorbable by human tissue, which ideally has a 50/50 cis/trans isomer ratio.

The benefits of delivering high concentrate bioavailable phytonutrients allows the body to more efficiently absorb the active and stable nutrients and antioxidants. For example, green tea, which is rich in antioxidants critical for protecting white and red blood cells and boosting the body's immune system, is not readily absorbed in its natural state. According to published research, the average person needs to consume 8-10 cups of green tea in order to receive a clinical dose of the necessary gallate catechins. Even the green tea extracts currently on the market lack the necessary bioavailable properties necessary for maximum absorption.

Mr. Duffield commented, "The CRS hydrodynamic process is able to address the release of select plant phytonutrients to maximize the efficiency of absorption, opening up the multi-billion dollar health and wellness market. By protecting the process of increasing bioavailability with intellectuals, this allows the company to focus on bringing the first botanical products to market -- products that we believe will exhibit demonstrably better benefits than what is currently available to consumers."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principal holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.


Contact:
Investor Relations
Tel: (425) 466-0212
Email: info@Plandaíbiotech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES